-
1.发明申请NOVEL ALPHA-1 ANTITRYPSIN VARIANT, PREPARATION METHOD THEREOF AND USE THEREOF 有权新型ALPHA-1抗体变体，其制备方法及其用途公开(公告)号：US20140371160A1
公开(公告)日：2014-12-18
申请号：US14344468
申请日：2012-08-13
申请人： Soon Jae Park , Hye-Shin Chung , Sang Mee Lee , Ji-Sun Kim
发明人： Soon Jae Park , Hye-Shin Chung , Sang Mee Lee , Ji-Sun Kim
IPC分类号： C07K14/81
CPC分类号： C07K14/8125 , A61K35/16 , A61K38/00 , A61K38/05 , A61K38/1709 , A61K38/177 , A61K39/00 , C07K5/06191 , C07K9/005 , C07K14/47 , C07K14/52 , C07K14/745 , C07K14/755 , C07K14/785 , C07K2319/00
摘要： A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t1/2) and the area under blood drug concentration vs. time curve (AUC) are remarkably increased by adding an N-glycosylation site in animal cells through amino acid mutation between 1st and 25th positions of the N-terminus of alpha-1 antitrypsin. Therefore, the alpha-1 antitrypsin variant can be useful in preventing or treating alpha-1 antitrypsin deficiency.
摘要翻译： 提供了一种新的α-1抗胰蛋白酶变体，其制备方法及其用途。 α-1抗胰蛋白酶变体在体内具有优异的稳定性，并且对弹性蛋白酶活性具有抑制作用，因为血液半衰期（t1 / 2）和血液药物浓度与时间曲线（AUC）之间的面积通过加入 通过在α-1抗胰蛋白酶的N末端的第1至第25位之间的氨基酸突变，动物细胞中的N-糖基化位点。 因此，α-1抗胰蛋白酶变体可用于预防或治疗α-1抗胰蛋白酶缺乏症。
-
2.发明授权公开(公告)号：US09051395B2
公开(公告)日：2015-06-09
申请号：US14344468
申请日：2012-08-13
申请人： Soon Jae Park , Hye-Shin Chung , Sang Mee Lee , Ji-Sun Kim
发明人： Soon Jae Park , Hye-Shin Chung , Sang Mee Lee , Ji-Sun Kim
IPC分类号： C07K14/81 , A61K39/00 , C07K5/06 , C07K14/745 , C07K14/755 , C07K14/785 , C07K14/52 , A61K38/05 , C07K9/00 , A61K35/16 , C07K14/47 , A61K38/17 , A61K38/00
CPC分类号： C07K14/8125 , A61K35/16 , A61K38/00 , A61K38/05 , A61K38/1709 , A61K38/177 , A61K39/00 , C07K5/06191 , C07K9/005 , C07K14/47 , C07K14/52 , C07K14/745 , C07K14/755 , C07K14/785 , C07K2319/00
摘要： A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t1/2) and the area under blood drug concentration vs. time curve (AUC) are remarkably increased by adding an N-glycosylation site in animal cells through amino acid mutation between 1st and 25th positions of the N-terminus of alpha-1 antitrypsin. Therefore, the alpha-1 antitrypsin variant can be useful in preventing or treating alpha-1 antitrypsin deficiency.
摘要翻译： 提供了一种新的α-1抗胰蛋白酶变体，其制备方法及其用途。 α-1抗胰蛋白酶变体在体内具有优异的稳定性，并且对弹性蛋白酶活性具有抑制作用，因为血液半衰期（t1 / 2）和血液药物浓度与时间曲线（AUC）之间的面积通过加入 通过在α-1抗胰蛋白酶的N末端的第1至第25位之间的氨基酸突变，动物细胞中的N-糖基化位点。 因此，α-1抗胰蛋白酶变体可用于预防或治疗α-1抗胰蛋白酶缺乏症。
-
3.发明申请IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASNG IN VIVO HALF-LIFE USING SAME 有权生活在生活中的寿命增加的融合蛋白或肽维持在体内释放，以及使用其增加生活的生命的方法公开(公告)号：US20120094356A1
公开(公告)日：2012-04-19
申请号：US13265775
申请日：2010-04-22
申请人： Hye-Shin Chung , Seung Bum Yoo , Sang Mee Lee
发明人： Hye-Shin Chung , Seung Bum Yoo , Sang Mee Lee
CPC分类号： C07K14/8125 , C07K2319/31
摘要： The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.
摘要翻译： 本发明涉及通过维持体内持续释放而增加其体内半衰期的融合蛋白或肽，以及使用其增加体内半衰期的方法。 根据本发明的融合蛋白或肽通过将生理活性蛋白或生理活性肽与一个或多个突变的氨基酸结合至α-1抗胰蛋白酶或α-1抗胰蛋白酶突变体而具有优异的体内稳定性，以维持体内持续 与固有的生理活性蛋白质或生理活性肽相比，释放并显着增加血液中的半衰期（T1 / 2）。 因此，根据本发明的融合蛋白或肽可用于开发蛋白质或肽药物的缓释制剂。
-
4.发明授权In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same 有权体内半衰期增加通过持续体内释放维持的融合蛋白或肽，以及使用其增加体内半衰期的方法公开(公告)号：US09012606B2
公开(公告)日：2015-04-21
申请号：US13265775
申请日：2010-04-22
申请人： Hye-Shin Chung , Seung Bum Yoo , Sang Mee Lee
发明人： Hye-Shin Chung , Seung Bum Yoo , Sang Mee Lee
CPC分类号： C07K14/8125 , C07K2319/31
摘要： The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.
摘要翻译： 本发明涉及通过维持体内持续释放而增加其体内半衰期的融合蛋白或肽，以及使用其增加体内半衰期的方法。 根据本发明的融合蛋白或肽通过将生理活性蛋白或生理活性肽与一个或多个突变的氨基酸结合至α-1抗胰蛋白酶或α-1抗胰蛋白酶突变体而具有优异的体内稳定性，以维持体内持续 与固有的生理活性蛋白质或生理活性肽相比，释放并显着增加血液中的半衰期（T1 / 2）。 因此，根据本发明的融合蛋白或肽可用于开发蛋白质或肽药物的缓释制剂。
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
